Zepbound 7.5 MG/0.5 ML pen 0.5ML
Ended Awarded Last action
- Contract number
- SPE2DR26F8N6X
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $8,793
Award facts
- Contract value 100% obligated
- $8,793.11 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order award from the Defense Logistics Agency valued at $8,793.11 for Zepbound 7.5 mg/0.5 mL pen injections. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of January 23, 2026, and was competitively awarded without set-aside restrictions. This delivery order falls under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle running through December 2026 that enables the company to supply an extensive range of pharmaceutical products and medical supplies to military healthcare systems worldwide.
The award supports the Defense Logistics Agency's mission to sustain military readiness by ensuring pharmaceutical product availability across the Defense Health System. AmerisourceBergen's parent company, Cencora, Inc. (formerly doing business as AmerisourceBergen), holds a separate single-award Indefinite Delivery Contract with DLA valued at up to $999,999,999.00 through December 31, 2031, further demonstrating the company's critical role in federal medical procurement. The delivery of Zepbound, a diabetes medication, aligns with DLA's broader pharmaceutical procurement strategy supporting military treatment facilities and veteran healthcare programs globally.
Quick answers
Who was awarded contract SPE2DR26F8N6X?
SPE2DR26F8N6X was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 22, 2026.
How much is contract SPE2DR26F8N6X worth?
The government has obligated $8,793 on SPE2DR26F8N6X.
Is contract SPE2DR26F8N6X an order under another contract?
Yes. SPE2DR26F8N6X is a delivery order under SPE2DR25D3022, an indefinite delivery contract.
Was contract SPE2DR26F8N6X competed?
The extent of competition for SPE2DR26F8N6X was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award